{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T05:27:46Z","timestamp":1786512466661,"version":"build-2736575974"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Neratinib, an irreversible pan-HER tyrosine kinase inhibitor, is a well-established extended adjuvant therapy for early-stage human epidermal growth factor receptor 2-positive (HER2+) breast cancer. However, its clinical application is often constrained by the high incidence of treatment-related diarrhea. This study sought to assess the dynamic changes in health-related quality of life (HRQoL) and the tolerability of neratinib, with a particular focus on dose escalation strategies and anti-diarrheal prophylaxis, within a real-world Chinese patient cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This single-center, prospective observational study included 31 female patients diagnosed with stage I-III HER2-positive breast cancer who initiated neratinib therapy following the completion of trastuzumab-based adjuvant treatment between October 2022 and January 2024. Patients were administered either non\u2013dose-escalation group (240 mg\/day) or dose-escalation group (120 mg\/160 mg daily during Week 1, 160 mg\/200 mg daily during Week 2, and 240 mg daily from Week 3 onward). Diarrhea management was conducted using prophylactic or on-demand loperamide. HRQoL was evaluated longitudinally through the EQ-5D-5L (health utility index and EQ visual analog scale [EQ VAS]) and Functional Assessment of Chronic Illness Therapy-Diarrhea (FACIT-D) questionnaires at predefined time points: baseline (D1), D30, D60, D90, D180, and D360. Diarrhea severity was graded according to Common Terminology Criteria for Adverse Events v5.0 (CTCAE v5.0) criteria. Statistical analyses encompassed descriptive statistics and Wilcoxon signed-rank tests.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The median age of the patients was 48 years (range: 37\u201365 years), with 58.1% and 41.9% classified as pathological stage II and III, respectively. A total of 64 diarrhea events were recorded (grade 1, 48.4%; grade 2, 50.0%; grade 3, 1.6%), with no grade 4 events or fatalities. Permanent discontinuation of treatment due to diarrhea occurred in 16.1% of patients, 23.5% in the dose-escalation group vs. 7.1% in the non-dose-escalation group. HRQoL temporarily declined during the early treatment phase, as evidenced by a reduction in the EQ-5D-5L health utility index from 0.96\u00a0\u00b1\u00a00.07 at baseline to 0.89\u00a0\u00b1\u00a00.15 at D30 (p=0.011) and a decrease in the EQ VAS score from 89.94\u00a0\u00b1\u00a09.92 to 84.16\u00a0\u00b1\u00a012.64 at D30 (p=0.018). However, HRQoL demonstrated progressive recovery from D90 onward, with scores surpassing baseline levels by D180 (EQ-5D-5L utility index: 0.96\u00a0\u00b1\u00a00.07; EQ VAS: 89.92\u00a0\u00b1\u00a07.74) and D360 (utility index: 0.97\u00a0\u00b1\u00a00.06; EQ VAS: 92.84\u00a0\u00b1\u00a07.19). The FACIT-D score showed an initial improvement (baseline: 58.81\u00a0\u00b1\u00a07.95 vs. D30: 66.90\u00a0\u00b1\u00a011.39, p=0.002), followed by stabilization at baseline levels from D180 onward. Notably, no disease recurrence or distant metastasis was observed in patients who completed the treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Neratinib-associated HRQoL impairment is transient, with initial declines primarily due to diarrhea, which typically resolves within 3\u20136 months of treatment. With the implementation of appropriate supportive measures, such as loperamide prophylaxis and dose modifications, the majority of patients experience sustained HRQoL recovery, and even improvement, over a 12-month period.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1828599","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T04:38:48Z","timestamp":1786509528000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Longitudinal evaluation of health-related quality of life in Chinese patients with early-stage HER2-positive breast cancer undergoing neratinib extended adjuvant therapy: a real-world prospective cohort study"],"prefix":"10.3389","volume":"16","author":[{"given":"Xuanhua","family":"Liang","sequence":"first","affiliation":[{"name":"Breast Center Zone One, Zhongshan City People\u2019s Hospital","place":["Zhongshan, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zibai","family":"Guo","sequence":"additional","affiliation":[{"name":"Breast Center Zone One, Zhongshan City People\u2019s Hospital","place":["Zhongshan, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhong","family":"Wei","sequence":"additional","affiliation":[{"name":"Breast Center Zone One, Zhongshan City People\u2019s Hospital","place":["Zhongshan, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anping","family":"Gui","sequence":"additional","affiliation":[{"name":"Breast Center Zone One, Zhongshan City People\u2019s Hospital","place":["Zhongshan, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengru","family":"Jian","sequence":"additional","affiliation":[{"name":"Breast Center Zone One, Zhongshan City People\u2019s Hospital","place":["Zhongshan, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Min","sequence":"additional","affiliation":[{"name":"Breast Center Zone One, Zhongshan City People\u2019s Hospital","place":["Zhongshan, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengwen","family":"Wang","sequence":"additional","affiliation":[{"name":"Breast Center Zone One, Zhongshan City People\u2019s Hospital","place":["Zhongshan, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shihui","family":"Ma","sequence":"additional","affiliation":[{"name":"Breast Center Zone One, Zhongshan City People\u2019s Hospital","place":["Zhongshan, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12885-023-10531-z","article-title":"A clinicopathological study and survival analysis of 99 breast cancers with HER2\/CEP17 ratio \u2265 2.0 and an average HER2 copy number < 4.0 per cell in China","volume":"23","author":"Zhou","year":"2023","journal-title":"BMC Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00551-3","article-title":"Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"17","author":"Chan","year":"2016","journal-title":"Lancet Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-03-2868","article-title":"Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase","volume":"64","author":"Rabindran","year":"2004","journal-title":"Cancer Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30717-9","article-title":"Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"18","author":"Martin","year":"2017","journal-title":"Lancet Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"56","DOI":"10.56782\/pps.298","article-title":"Evaluation of pharmaceutical potentials of naturally and in vitro-grown wild strawberry (Fragaria vesca L.)","volume":"23","author":"Birinci Yildirim","year":"2025","journal-title":"Prospects Pharm Sci"},{"key":"B8","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s10549-018-05102-x","article-title":"The characterization, management, and future considerations for ErbB-family TKI-associated diarrhea","volume":"175","author":"Rugo","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1177\/10732748241278039","article-title":"Management and mechanisms of diarrhea induced by tyrosine kinase inhibitors in human epidermal growth factor receptor-2-positive breast cancer","volume":"31","author":"Sun","year":"2024","journal-title":"Cancer Control"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.05.012","article-title":"Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: The CONTROL trial","volume":"31","author":"Barcenas","year":"2020","journal-title":"Ann Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-012-0322-4","article-title":"Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: A multi-country study","volume":"22","author":"Janssen","year":"2013","journal-title":"Qual Life Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual Life Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-1-79","article-title":"The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties, applications, and interpretation","volume":"1","author":"Webster","year":"2003","journal-title":"Health Qual Life Outcomes"},{"key":"B14","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/s0885-3924(96)00274-6","article-title":"Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system","volume":"13","author":"Yellen","year":"1997","journal-title":"J Pain Symptom Manage"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.18085","article-title":"Two-year survival comparing web-based symptom monitoring vs routine surveillance following treatment for lung cancer","volume":"321","author":"Denis","year":"2019","journal-title":"JAMA"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.7156","article-title":"Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment","volume":"318","author":"Basch","year":"2017","journal-title":"JAMA"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2016.11.016","article-title":"Estimating an EQ-5D-5L value set for China","volume":"20","author":"Luo","year":"2017","journal-title":"Value Health"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1177\/0163278705275340","article-title":"Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience","volume":"28","author":"Yost","year":"2005","journal-title":"Eval Health Professions"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-12-104","article-title":"PhyloSim - Monte Carlo simulation of sequence evolution in the R statistical computing environment","volume":"12","author":"Sipos","year":"2011","journal-title":"BMC Bioinf"},{"key":"B20","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13058-019-1112-5","article-title":"Patterns of occurrence and implications of neratinib-associated diarrhea in patients with HER2-positive breast cancer: Analyses from the randomized phase III ExteNET trial","volume":"21","author":"Mortimer","year":"2019","journal-title":"Breast Cancer Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00147","article-title":"Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with \u2265 2 HER2-directed regimens: Phase III NALA trial","volume":"38","author":"Saura","year":"2020","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz016","article-title":"Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: Longitudinal analyses from the randomized phase III ExteNET trial","volume":"30","author":"Delaloge","year":"2019","journal-title":"Ann Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"594","DOI":"10.6004\/jnccn.2023.0031","article-title":"NCCN guidelines\u00ae Insights: breast cancer, version 4.2023","volume":"21","author":"Gradishar","year":"2023","journal-title":"J Natl Compr Cancer Netw"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq413","article-title":"The relation between information provision and health-related quality of life, anxiety and depression among cancer survivors: A systematic review","volume":"22","author":"Husson","year":"2011","journal-title":"Ann Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/j.pain.0000000000003798","article-title":"Real-world data and evidence in pain research: An IMMPACT comprehensive review and best practice recommendations","volume":"167","author":"Vollert","year":"2026","journal-title":"Pain"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.051718","article-title":"Emulating randomized clinical trials with nonrandomized real-world evidence studies: First results from the RCT DUPLICATE initiative","volume":"143","author":"Franklin","year":"2021","journal-title":"Circulation"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2017.08.3019","article-title":"Good practices for real-world data studies of treatment and\/or comparative effectiveness: Recommendations from the joint ISPOR-ISPE special task force on real-world evidence in health care decision making","volume":"20","author":"Berger","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2015.222","article-title":"Patient-reported outcomes in the evaluation of toxicity of anticancer treatments","volume":"13","author":"Di Maio","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s41687-018-0091-0","article-title":"Exploring the implementation of patient-reported outcome measures in cancer care: Need for more real-world evidence results in the peer reviewed literature","volume":"2","author":"Anatchkova","year":"2018","journal-title":"J Patient Rep Outcomes"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.04.007","article-title":"The role of patient-reported outcome measures in the continuum of cancer clinical care: ESMO clinical practice guideline","volume":"33","author":"Di Maio","year":"2022","journal-title":"Ann Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00069","article-title":"Biomarkers for adjuvant endocrine and chemotherapy in early-stage breast cancer: ASCO guideline update","volume":"40","author":"Andre","year":"2022","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1828599\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T04:38:58Z","timestamp":1786509538000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1828599\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":31,"alternative-id":["10.3389\/fonc.2026.1828599"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1828599","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]},"article-number":"1828599"}}